Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 43215
Los Alamitos, CA
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 43215
Los Alamitos, CA
Click here to add this to my saved trials
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
334
mi
from 43215
Glendale, WI
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
334
mi
from 43215
Glendale, WI
Click here to add this to my saved trials
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
494
mi
from 43215
New Hyde Park, NY
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
494
mi
from 43215
New Hyde Park, NY
Click here to add this to my saved trials
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Research Site
1006
mi
from 43215
Stafford, TX
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Research Site
1006
mi
from 43215
Stafford, TX
Click here to add this to my saved trials
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from 43215
Mendoza,
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from 43215
Mendoza,
Click here to add this to my saved trials
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
559
mi
from 43215
Rochester, MN
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
354
mi
from 43215
Durham, NC
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
4064
mi
from 43215
Leuven,
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
4064
mi
from 43215
Leuven,
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2003
mi
from 43215
Thousand Oaks, CA
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2003
mi
from 43215
Thousand Oaks, CA
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
792
mi
from 43215
Orlando, FL
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated:  12/31/1969
Research Site
4831
mi
from 43215
Debrecen,
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Enrolling
Updated: 12/31/1969
Research Site
4831
mi
from 43215
Debrecen,
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
622
mi
from 43215
Little Rock, AR
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
970
mi
from 43215
Fort Lauderdale, FL
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
970
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
922
mi
from 43215
Fort Myers, FL
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
922
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
993
mi
from 43215
Miami, FL
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
4052
mi
from 43215
Bruxelles,
Study of IFN-K in Systemic Lupus Erythematosus
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
4052
mi
from 43215
Bruxelles,
Click here to add this to my saved trials
Insulin Resistance and Atherosclerosis in Women With Lupus
Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Insulin Resistance and Atherosclerosis in Women With Lupus
Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Emory University
435
mi
from 43215
Atlanta, GA
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Emory University
435
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's HospitL
640
mi
from 43215
Boston, MA
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's HospitL
640
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Northwell Health
492
mi
from 43215
Great Neck, NY
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Northwell Health
492
mi
from 43215
Great Neck, NY
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Allegheny Health Network
163
mi
from 43215
PIttsburgh, PA
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Allegheny Health Network
163
mi
from 43215
PIttsburgh, PA
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Alberta
1700
mi
from 43215
Edmonton,
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Alberta
1700
mi
from 43215
Edmonton,
Click here to add this to my saved trials
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Arizona Arthritis Center; University Physicians Pediatrics
1639
mi
from 43215
Tucson, AZ
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Arizona Arthritis Center; University Physicians Pediatrics
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
HCP Clinical Research, LLC
1969
mi
from 43215
Huntington Beach, CA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
HCP Clinical Research, LLC
1969
mi
from 43215
Huntington Beach, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Valerius Medical Group & Research Ctr of Greater Long Beach
1969
mi
from 43215
Los Alamitos, CA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Valerius Medical Group & Research Ctr of Greater Long Beach
1969
mi
from 43215
Los Alamitos, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sutter Gould Medical Foundation
2032
mi
from 43215
Modesto, CA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sutter Gould Medical Foundation
2032
mi
from 43215
Modesto, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
1984
mi
from 43215
Torrance, CA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
1984
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
New England Research Associates, Llc
521
mi
from 43215
Trumbull, CT
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
New England Research Associates, Llc
521
mi
from 43215
Trumbull, CT
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
RASF Clinical Research Center
955
mi
from 43215
Boca Raton, FL
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
RASF Clinical Research Center
955
mi
from 43215
Boca Raton, FL
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Bay Area Arthritis and Osteoporosis
834
mi
from 43215
Brandon, FL
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Bay Area Arthritis and Osteoporosis
834
mi
from 43215
Brandon, FL
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Clinical Research of West Florida, Inc.
827
mi
from 43215
Tampa, FL
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Clinical Research of West Florida, Inc.
827
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Institute of Arthritis Research
1506
mi
from 43215
Idaho Falls, ID
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Institute of Arthritis Research
1506
mi
from 43215
Idaho Falls, ID
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center Research Institute, Inc.; Phase 1
621
mi
from 43215
Fairway, KA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center Research Institute, Inc.; Phase 1
621
mi
from 43215
Fairway, KA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Via Christi Research, a division of Via Christi Hospitals Wichita, Inc.
783
mi
from 43215
Wichita, KA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Via Christi Research, a division of Via Christi Hospitals Wichita, Inc.
783
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
801
mi
from 43215
Baton Rouge, LA
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
801
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials